Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloride

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Oct 13, 2017 → Oct 31, 2018

NCT ID

NCT03300362

About Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloride

Seasonal influenza vaccine + MVA-NP+M1 + Sodium chloride is a phase 2 stage product being developed by Barinthus Biotherapeutics for Influenza. The current trial status is terminated. This product is registered under clinical trial identifier NCT03300362. Target conditions include Influenza.

What happened to similar drugs?

20 of 20 similar drugs in Influenza were approved

Approved (20) Terminated (1) Active (0)

✅Monovalent Influenza VaccineAstraZenecaApproved

✅Trivalent Influenza VaccineAstraZenecaApproved

✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved

✅Trivalent Influenza Virus VaccineAstraZenecaApproved

✅Vaxelis + PedvaxHIBMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03300362	Phase 2	Terminated	Oct 13, 2017	Oct 31, 2018	Influenza

Competing Products

20 competing products in Influenza

See all competitors

Product	Company	Stage
mRNA-1010	Moderna	Phase 1
mRNA-1273	Moderna	Phase 1
mRNA-1010	Moderna	Phase 2
mRNA-1083 Composition 1 Dose A Lot A	Moderna	Phase 2
mRNA-1010	Moderna	Phase 3
mRNA-1011.1	Moderna	Phase 2
mRNA-1083.1	Moderna	Phase 2
mRNA-1010	Moderna	Phase 3
mRNA-1083	Moderna	Phase 3
mRNA-1073	Moderna	Phase 2
VAL-506440	Moderna	Phase 1
mRNA-1083	Moderna	Phase 3
mRNA-1083	Moderna	Phase 2
mRNA-1010	Moderna	Phase 3
VAL-339851	Moderna	Phase 1
mRNA-1018-H5	Moderna	Phase 3
mRNA-1653	Moderna	Phase 1
mRNA-1030	Moderna	Phase 2
mRNA-1018 for H5N8	Moderna	Phase 2
mRNA-1653	Moderna	Phase 1